BioNTech Has Had a Rough Year. Why It's a Stock Worth Owning

BioNTech, like all Covid-19 vaccine makers, has gotten crunched in 2023. But it has so much cash that it would have appealed to Warren Buffett’s mentor,...

Related Keywords

Benjamin Graham , Andrew Bary , Warren Buffett , Pfizer , Article Normal , Biotechnology Services , Pharmaceuticals , Vaccines , Healthcare Life Sciences , Biopharmaceuticals , Specialized Drugs Medications , Political General News , Health , Immunizations , Medical Treatments Procedures , Synd , Biotech And Pharma , Companies , Healthcare , Biontech Se , Bntx , Biontech , Political , General News , Medical Treatments , Procedures , Life Sciences , Specialized Drugs , Medications ,